Literature DB >> 3634296

Characterization of bovine surfactant for infants with respiratory distress syndrome.

H W Taeusch, K M Keough, M Williams, R Slavin, E Steele, A S Lee, D Phelps, N Kariel, J Floros, M E Avery.   

Abstract

Exogenous surfactant treatment of surfactant-deficient disease states is now under study in a number of centers, using a variety of surfactant preparations. We have chosen one preparation because of its current and potential clinical usefulness, and we have characterized it using selected tests and assays that we thought would be necessary (although not necessarily sufficient) to justify extended clinical use. We found its lipid composition to resemble that of other surfactants derived from lung mince. There is little variation among several batches with regard to lipid composition or surface tension-lowering capability. Morphologic heterogeneity occurs in individual samples of pelleted material studied by electron microscopy. Arterial oxygenation is improved when the material is administered to animals depleted of surfactant. A low molecular weight protein was identified that reacted with antibody that specifically binds nonserum surfactant proteins in a number of animal species (including human and cow). The characteristics of this surfactant preparation should be useful for comparison as newer and simpler products become available.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3634296

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  Effects of lung surfactant proteins, SP-B and SP-C, and palmitic acid on monolayer stability.

Authors:  J Ding; D Y Takamoto; A von Nahmen; M M Lipp; K Y Lee; A J Waring; J A Zasadzinski
Journal:  Biophys J       Date:  2001-05       Impact factor: 4.033

3.  Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

4.  Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity.

Authors:  S D Revak; T A Merritt; E Degryse; L Stefani; M Courtney; M Hallman; C G Cochrane
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  Stable microbubble test for predicting the risk of respiratory distress syndrome: I. Comparisons with other predictors of fetal lung maturity in amniotic fluid.

Authors:  S Chida; T Fujiwara
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

6.  A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome.

Authors:  J D Horbar; R F Soll; H Schachinger; G Kewitz; H T Versmold; W Lindner; G Duc; D Mieth; O Linderkamp; E P Zilow
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

Review 7.  The fate of exogenous surfactant in neonates with respiratory distress syndrome.

Authors:  M Hallman; T A Merritt; K Bry
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

8.  Surfactant replacement therapy in neonatal respiratory distress syndrome. A multi-centre, randomized clinical trial: comparison of high- versus low-dose of surfactant TA.

Authors:  M Konishi; T Fujiwara; T Naito; Y Takeuchi; Y Ogawa; K Inukai; M Fujimura; H Nakamura; T Hashimoto
Journal:  Eur J Pediatr       Date:  1988-01       Impact factor: 3.183

9.  Lipid bilayer surface association of lung surfactant protein SP-B, amphipathic segment detected by flow immunofluorescence.

Authors:  M L Longo; A Waring; J A Zasadzinski
Journal:  Biophys J       Date:  1992-09       Impact factor: 4.033

Review 10.  How Mary Ellen Avery Influenced my Career as an Investigator.

Authors:  Cynthia Frances Bearer
Journal:  Front Pediatr       Date:  2014-04-24       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.